Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (29)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by BOLUMAR, F.
Right arrow Articles by REBAGLIATO, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by BOLUMAR, F.
Right arrow Articles by REBAGLIATO, M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1996 Oxford University Press

research-article

Prevalence of Antibodies to Hepatitis C in a Population of Intravenous Drug Users in Valencia, Spain, 1990–1992

FRANCISCO BOLUMAR * , ILDEFONSO HERNANDEZ-AGUADO * ,, LIDIA FERRER {dagger} , ISABEL RUIZ {dagger} , Ma JOSÉ AVIÓ {dagger} and MARISA REBAGLIATO *

* Departamento de Salud Pública, Universidad de Alicante Apartado de Correos 374, 03080 Alicante, Spain.
{dagger} Instituto Valenciano de Estudios en Salud Pública Spain.

Reprint requests to: Dr IIdefonso Hernández-Aguado.

BACKGROUND: Hepatitis C has been related to other viral diseases such as the human Immunodeficiency virus infection (HIV) or hepatitis B (HBV). The objective of this study was to estimate the prevalence and determinants of antibodies to hepatitis C virus (HCV) in intravenous drug users (IVDU) in Valencia (Spain) and to compare the seroprevalence between the HCV, HIV and HBV in this high risk group.

METHODS: A cross-sectional study was conducted in a sample of 1056 current IVDU from the Valencia area who attended the city's AIDS Information Centre between January 1990 and December 1992. Information on sociodemographic, sexual behaviour, and drug use vanables was collected by means of a structured questionnaire. Antibodies to HCV, HIV and HBV were assayed by ELISA test.

RESULTS: The seroprevalence of HCV for the whole period was 85.5% (95% confidence Interval [Cl]: 83.2–87.5%), ranging from 76.5% in 1990 (95% Cl : 71.9–81.1%) to 87.8% in 1992 (95% Cl : 82.5–93.1%). Year of testing and prevalence of HBV markers showed an independent association with HCV seroprevalence. When only IVDU aged <25 years were analysed, sharing of needles also appeared as an independent determinant. Of those IVDU with less than one year of addiction, 69% were HCV seropositive compared with 41% for HBV and 14% for HIV.

CONCLUSIONS: Intravenous drug users in Valencia showed one of the highest reported hepatitis C seroprevalences (85.5%). A more efficient parenteral transmission of hepatitis C virus than HBV or HIV is suggested.

Keywords hepatitis, substance abuse, sexual behaviour, prevalence

Revised 1 July 1995


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J. Gen. Virol.Home page
N. Jimenez-Hernandez, M. Torres-Puente, M. A. Bracho, I. Garcia-Robles, E. Ortega, J. del Olmo, F. Carnicer, F. Gonzalez-Candelas, and A. Moya
Epidemic dynamics of two coexisting hepatitis C virus subtypes
J. Gen. Virol., January 1, 2007; 88(1): 123 - 133.
[Abstract] [Full Text] [PDF]


Home page
Int J EpidemiolHome page
B. P Smyth, J. Barry, and E. Keenan
Irish injecting drug users and hepatitis C: the importance of the social context of injecting
Int. J. Epidemiol., February 1, 2005; 34(1): 166 - 172.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.